Study will evaluate the real-world effectiveness of Depo-Eligard® after six months of treatment

The study will provide data on the tolerance, safety and acceptance of Depo-Eligard® (leuproreline acetate) when used in routine clinical practice. Data on efficacy parameters such as testosterone, PSA levels, symptoms and treatment failure, if available will be collected.It will reflect the way Depo-Eligard® is used in routine clinical practice and how PSA, testosterone levels, symptoms and treatment failure, are used as parameters in the treatment for Prostate Cancer.

Patient data will be collected after a treatment period of six months.

Inclusion Criteria:

• Patients having been prescribed Depo-Eligard® in accordance with the terms of the marketing authorization
• Patients on treatment with Depo-Eligard® for at least six months
• Written consent has been obtained

Patients from Belgian participating investigator sites having been prescribed Depo-Eligard® in accordance with the terms of the marketing authorization, on treatment with Depo-Eligard® for at least six months.